autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Cellectar Biosciences's portfolio.
pharma · Waldenstrom Macroglobulinemia · Non Small Cell Lung Cancer · CLRB
Cellectar Biosciences
Cellectar Biosciences drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
100 Campus Dr, 207, Florham Park, New Jersey 07932, US HQ
21 Employees
Public company Type
CLRB · NYSE Ticker
Company details
- Status
- Public
- HQ
- 100 Campus Dr, 207, Florham Park, New Jersey 07932, US
- Employees
- 21
- Programs
- 17
- Drugs
- 7
- Patents
- 7
Cellectar Biosciences pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cellectar Biosciences drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Cellectar Biosciences in public FDA and regional records.
-
Development asset linked to Cellectar Biosciences in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Cellectar Biosciences in public FDA and regional records.